261 related articles for article (PubMed ID: 29360266)
1. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Staberg M; Rasmussen RD; Michaelsen SR; Pedersen H; Jensen KE; Villingshøj M; Skjoth-Rasmussen J; Brennum J; Vitting-Seerup K; Poulsen HS; Hamerlik P
Mol Oncol; 2018 Mar; 12(3):406-420. PubMed ID: 29360266
[TBL] [Abstract][Full Text] [Related]
2. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
[TBL] [Abstract][Full Text] [Related]
3. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.
Kurt IC; Sur I; Kaya E; Cingoz A; Kazancioglu S; Kahya Z; Toparlak OD; Senbabaoglu F; Kaya Z; Ozyerli E; Karahüseyinoglu S; Lack NA; Gümüs ZH; Onder TT; Bagci-Onder T
Cell Death Dis; 2017 Jun; 8(6):e2897. PubMed ID: 28661478
[TBL] [Abstract][Full Text] [Related]
4. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.
Kottakis F; Foltopoulou P; Sanidas I; Keller P; Wronski A; Dake BT; Ezell SA; Shen Z; Naber SP; Hinds PW; McNiel E; Kuperwasser C; Tsichlis PN
Cancer Res; 2014 Jul; 74(14):3935-46. PubMed ID: 24853546
[TBL] [Abstract][Full Text] [Related]
5. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
He J; Nguyen AT; Zhang Y
Blood; 2011 Apr; 117(14):3869-80. PubMed ID: 21310926
[TBL] [Abstract][Full Text] [Related]
6. KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin-1-mediated chromatin silencing.
Kang JY; Kim JY; Kim KB; Park JW; Cho H; Hahm JY; Chae YC; Kim D; Kook H; Rhee S; Ha NC; Seo SB
FASEB J; 2018 Oct; 32(10):5737-5750. PubMed ID: 29763382
[TBL] [Abstract][Full Text] [Related]
7. Lysine demethylase 2B regulates angiogenesis via Jumonji C dependent suppression of angiogenic transcription factors.
Sasaki Y; Higashijima Y; Suehiro JI; Sugasawa T; Oguri-Nakamura E; Fukuhara S; Nagai N; Hirakawa Y; Wada Y; Nangaku M; Kanki Y
Biochem Biophys Res Commun; 2022 May; 605():16-23. PubMed ID: 35306360
[TBL] [Abstract][Full Text] [Related]
8. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
Liau BB; Sievers C; Donohue LK; Gillespie SM; Flavahan WA; Miller TE; Venteicher AS; Hebert CH; Carey CD; Rodig SJ; Shareef SJ; Najm FJ; van Galen P; Wakimoto H; Cahill DP; Rich JN; Aster JC; Suvà ML; Patel AP; Bernstein BE
Cell Stem Cell; 2017 Feb; 20(2):233-246.e7. PubMed ID: 27989769
[TBL] [Abstract][Full Text] [Related]
9. Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Ramadoss S; Guo G; Wang CY
Oncogene; 2017 Jan; 36(1):47-59. PubMed ID: 27270439
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation.
Mallm JP; Windisch P; Biran A; Gal Z; Schumacher S; Glass R; Herold-Mende C; Meshorer E; Barbus M; Rippe K
Int J Cancer; 2020 Mar; 146(5):1281-1292. PubMed ID: 31456217
[TBL] [Abstract][Full Text] [Related]
11. The role of histone H3 lysine demethylases in glioblastoma.
Young D; Guha C; Sidoli S
Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
[TBL] [Abstract][Full Text] [Related]
12. Depletion of histone demethylase KDM2A inhibited cell proliferation of stem cells from apical papilla by de-repression of p15INK4B and p27Kip1.
Gao R; Dong R; Du J; Ma P; Wang S; Fan Z
Mol Cell Biochem; 2013 Jul; 379(1-2):115-22. PubMed ID: 23559091
[TBL] [Abstract][Full Text] [Related]
13. Alternative isoforms of KDM2A and KDM2B lysine demethylases negatively regulate canonical Wnt signaling.
Lađinović D; Pinkas D; Šopin T; Raška O; Liška F; Raška I; Vacík T
PLoS One; 2020; 15(10):e0236612. PubMed ID: 33104714
[TBL] [Abstract][Full Text] [Related]
14. CBP-triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer.
Qi Y; Zhao Y
J Cell Physiol; 2020 Mar; 235(3):2901-2910. PubMed ID: 31531877
[TBL] [Abstract][Full Text] [Related]
15. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells.
Tzatsos A; Paskaleva P; Lymperi S; Contino G; Stoykova S; Chen Z; Wong KK; Bardeesy N
J Biol Chem; 2011 Sep; 286(38):33061-9. PubMed ID: 21757686
[TBL] [Abstract][Full Text] [Related]
16. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
17. Identification of Structural Elements of the Lysine Specific Demethylase 2B CxxC Domain Associated with Replicative Senescence Bypass in Primary Mouse Cells.
Deiktakis EE; Abrams M; Tsapara A; Stournaras C; Tsatsanis C; Tsichlis PN; Kampranis SC
Protein J; 2020 Jun; 39(3):232-239. PubMed ID: 32270414
[TBL] [Abstract][Full Text] [Related]
18. Histone H3K79 demethylation by KDM2B facilitates proper DNA replication through PCNA dissociation from chromatin.
Kang JY; Park JW; Hahm JY; Jung H; Seo SB
Cell Prolif; 2020 Nov; 53(11):e12920. PubMed ID: 33029857
[TBL] [Abstract][Full Text] [Related]
19. Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.
Lin CA; Rhodes CT; Lin C; Phillips JJ; Berger MS
Cell Cycle; 2017 Apr; 16(8):765-775. PubMed ID: 28278055
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S
Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
